KPV vs LL-37
KPV (Alpha-MSH-derived tripeptide fragment) and LL-37 (Cathelicidin antimicrobial peptide) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | KPV | LL-37 |
|---|---|---|
| Compound class | Alpha-MSH-derived tripeptide fragment | Cathelicidin antimicrobial peptide |
| Research category | Healing & Recovery | Healing & Recovery |
| Length (amino acids) | 3 amino acids | 37 amino acids |
| Molecular weight | 342.43 g/mol | ~4493 Da |
| Half-life | Not documented | Not documented |
| Origin | KPV is a synthetic tripeptide corresponding to the C-terminal three amino acids (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring melanocortin peptide. It is studied as a fragment that retains some anti-inflammatory properties of the parent hormone. | LL-37 is a naturally occurring human antimicrobial peptide, the active fragment released from the C-terminal region of the human cathelicidin precursor protein hCAP18. It is part of the innate immune system and is expressed by neutrophils and various epithelial cells. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How KPV works
KPV is reported in preclinical studies to exert anti-inflammatory effects, and research has explored both melanocortin-receptor-dependent signaling and intracellular actions independent of classic MSH pigmentation activity. It has been studied for downregulation of pro-inflammatory signaling such as NF-kB-associated pathways in cell and animal models of colitis. These findings derive from in-vitro and rodent research.
How LL-37 works
LL-37 is a cationic, amphipathic host-defense peptide that can disrupt microbial membranes, giving it broad antimicrobial activity. Beyond direct killing, it has immunomodulatory roles, including chemotactic effects on immune cells, modulation of inflammatory signaling, and reported influence on angiogenesis and wound healing. These roles are documented in in-vitro and animal studies as part of innate immunity.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
KPV
LL-37
What sets each apart
KPV
KPV is distinguished by its melanocortin-pathway anti-inflammatory focus, in contrast to the antimicrobial LL-37 or the tissue-repair emphasis of BPC-157 and TB-500.
LL-37
LL-37 is unique in this group as a natural host-defense peptide combining direct antimicrobial activity with immune modulation, rather than being a synthetic repair-focused peptide.
Frequently asked questions
What is KPV?
KPV is the C-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains much of the parent hormone's anti-inflammatory activity while lacking its pigment-stimulating (melanocortin) effects. It is studied as a small anti-inflammatory peptide rather than as an approved therapeutic.
What is KPV studied for?
Preclinical research examines KPV for anti-inflammatory effects, particularly in models of intestinal inflammation and colitis, as well as skin inflammation. It is reported to enter cells and inhibit NF-kB signaling and pro-inflammatory cytokine production, and it can be transported into intestinal cells via the PepT1 transporter. No human clinical trials have confirmed these effects.
How does KPV produce anti-inflammatory effects without affecting pigmentation?
KPV corresponds only to the C-terminal tripeptide of alpha-MSH, so it preserves the anti-inflammatory activity associated with that region while omitting the sequence needed to activate melanocortin receptors that drive pigmentation. Mechanistically it is described as acting intracellularly on the NF-kB pathway, including inhibition of IkB kinase.
Is LL-37 an approved drug?
No. LL-37 is an endogenous human peptide studied as a research compound and antimicrobial-peptide template; it is not an approved therapeutic. Its evidence base is preclinical and mechanistic. It is sometimes discussed alongside KPV in immune-modulation and antimicrobial research.
What is LL-37?
LL-37 is the sole human cathelicidin antimicrobial peptide, a 37-amino-acid amphipathic alpha-helical peptide released from the C-terminal region of the hCAP18 precursor. It is named for its two leading leucine residues and its length. It functions in the innate immune system as a first-line defense at sites of infection, inflammation, and wounds.
What is LL-37 studied for?
Research examines LL-37 for direct antimicrobial activity against bacteria, and for antiviral, immunomodulatory, angiogenic, and wound-healing roles. Multiple patents describe LL-37 and its derivatives for wound healing. It is also studied in the context of inflammatory and autoimmune conditions, where it can present nucleic acids to immune receptors.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.